Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.66 USD
Change Today -0.01 / -0.21%
Volume 55.9K
ALQA On Other Exchanges
As of 3:21 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

alliqua biomedical inc (ALQA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/6/14 - $7.20
52 Week Low
10/28/14 - $3.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alliqua biomedical inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua biomedical inc (ALQA) Details

Alliqua BioMedical, Inc. provides wound care solutions. The company offers Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through its direct sales force; and an independent network of agents. The company is headquartered in Langhorne, Pennsylvania.

47 Employees
Last Reported Date: 02/24/15

alliqua biomedical inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $682.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $376.8K
Chief Operating Officer
Total Annual Compensation: $376.8K
Compensation as of Fiscal Year 2014.

alliqua biomedical inc (ALQA) Key Developments

Alliqua Biomedical, Inc. Announces Preliminary Revenue Results for the First Quarter Ended March 31, 2015; Updates Revenue Guidance for the Fiscal Year 2015

Alliqua BioMedical, Inc. announced preliminary revenue results for the first quarter ended March 31, 2015. For the quarter, total revenue increased approximately 258% year-over-year to approximately $2.1 million. Revenue result in excess of $2 million was driven by solid contributions from proprietary products segment, particularly Sorbion franchise, and strong growth in contract manufacturing business. The company updated revenue guidance for the fiscal year 2015. The company now expects total revenue in a range of $16.3 million to $18.8 million, compared to a previous expectation of revenue in a range of $15.5 million to $18 million.

Alliqua BioMedical, Inc., Annual General Meeting, May 06, 2015

Alliqua BioMedical, Inc., Annual General Meeting, May 06, 2015., at 09:00 US Eastern Standard Time. Location: Sheraton Bucks County Hotel. Agenda: To consider the election of seven directors to serve on board of directors for a term of one year or until their respective successors are elected and qualified; to consider the Alliqua, Inc. 2014 Long-Term incentive plan; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to consider the such other business as may properly come before the annual meeting.

Alliqua, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Revised Revenue Guidance for the Year Ending December 31, 2015

Alliqua, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company’s total revenue increased 255% year-over-year to approximately $1.7 million compared to $468,834 in last year. Organic revenue growth was 128% year-over-year. Loss from operations was $5.3 million compared to $13.4 million last year. Net loss attributable to common stockholders was $5.4 million or $0.34 per basic and diluted share, compared to $15.4 million or $1.68 per basic and diluted share for the same period last year. Loss before income tax provision was $5.3 million compared to $14.9 million for the last year. For the year, the company’s total revenue increased $3.0 million, or 166% year-over-year, to $4.8 million compared to $1.8 million in last year. Net loss for attributable to common stockholders was $25.4 million or $1.74 per basic and diluted share compared to a net loss of $22.4 million or $3.14 per basic and diluted share for the same period last year. Loss from operations was $25.4 million compared to $20.14 million and loss before income tax provision was $25.4 million compared to $22.4 million for the last year. The company is updating its revenue guidance for the fiscal year 2015 period. The updated guidance reflects the expected incremental contributions from the acquisition of Celleration, based on a closing date of June 30th. For the fiscal-year ending December 31, 2015, the company expects total revenue of $15.5 million to $18 million, representing growth at the mid-point of the range of approximately 250% year-over-year. This compares to the Company's previous expectation for total revenue in fiscal year 2015 in the range of $11 million to $13 million. The company expects sales from contract manufacturing business to reflect slightly positive growth year-over-year, therefore, the growth rates reflected in the company's revenue guidance for fiscal year 2015 are primarily generated by expected growth in the sale of the company's proprietary products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $4.66 USD -0.01

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr510.00 DKK -19.00
Derma Sciences Inc $7.56 USD -0.03
Smith & Nephew PLC 1,120 GBp +6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.4x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA BIOMEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at